ArticleScientific reports2025
Elevated oxytocin levels and oxytocin receptor gene expression in female-to-male transgender individuals.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Gender dysphoria (GD) is defined as a condition wherein a person's gender identity does not align with the sex assigned at birth. Oxytocin (OXT) is an essential neuromodulator involved in cognition and socio-emotional processing. Its central effects are exerted via oxytocin receptors (OXTR). Recent studies indicated that the changes in the levels of OXTR may influence the course of some mental disorders (obsessive-compulsive disorders, schizophrenia, depression and autism). Understanding the neurobiological underpinnings of GD, particularly the involvement of OXT and OXTR, could provide beneficial insights into the mechanisms underlying this condition. In the present study, 18 Female-to-Male (FtM) transgenders, 11 FtM transgenders with self-injection of testosterone (FtM-T), and 30 control cis-females were included. Plasma levels of hormones of OXT, estradiol, progesterone, LH, FSH, free testosterone, and testosterone were evaluated with an enzyme-linked immunosorbent assay (ELISA) kit. The whole blood mRNA expression of OXTR was determined via RT-qPCR. Our results showed a statistically significant increase in OXT plasma level in FtM group compared to control group (P = 0.032). Also, OXTR gene expression was significantly high in FtM-T group compared to cis-females group (P = 0.004). This is the first demonstration of increased plasma OXT levels in FtM transgenders and OXTR gene expression in FtM-T transgenders compared to the cis-females group. The results of this study can create a new approach to understanding the underlying mechanism of gender dysphoria. Further studies are necessary to ascertain whether this contributes to or is a consequence of GD symptomatology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.